Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer

Resistance is an obstacle to endocrine therapy for breast cancer. We measured levels of hypoxia-inducible factor (HIF)-1α in 52 primary breast cancer patients before and after receiving neoadjuvant endocrine therapy with letrozole for at least 3 months. Pre-treatment levels of HIF-1α were associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Xiaoqing, Hong, Qi, Lei, Li, Li, Daqiang, Li, Jianwei, Mo, Miao, Wang, Yujie, Shao, Zhimin, Shen, Zhenzhou, Cheng, Jingyi, Liu, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496173/
https://www.ncbi.nlm.nih.gov/pubmed/25929338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496173/
https://www.ncbi.nlm.nih.gov/pubmed/25929338

Ejemplares similares